Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?

Cancer Investigation

Volumn 24, Issue 4, 2006, Pages 461-465

  Diehl, V ^a   Behringer, K ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Advanced stage; BEACOPP; Chemotherapy treatment; Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CONSENSUS; DRUG EFFICACY; EUROPE; GERMANY; HODGKIN DISEASE; HUMAN; MYELODYSPLASTIC SYNDROME; OUTPATIENT CARE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; PREDNISONE; PROCARBAZINE; VINCRISTINE;

EID: 33745314248     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600705789     Document Type: Article

References (10)

1. Diehl, V.; Brillant, C.; Franklin, J.; et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12- trials of the German Hodgkin Study Group (GHSG). Blood 2004, 104 (11)A, 307.
2. Duggan, D.B.T.; Petroni, G.R.; Johnson, J.L.; et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J. Clin. Oncol. 2003, 21 (4), 607-614.
3. Loeffler, M.; Hasenclever, D.; Diehl, V. Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann. Oncol. 1998, 9 (Suppl. 5), S73-S78.
4. Diehl, V. Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG). Ann. Hematol. 1993, 66, 139-140.
5. Diehl, V.; Sieber, M.; Ruffer, U.; et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann. Oncol. 1997, 8, 143-148.
6. Diehl, V.; Franklin, J.; Pfreundschuh, M.; et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N. Engl. J. Med. 2003, 348 (24), 2386-2395.
7. Sieber, M.; Bredenfeld, H.; Josting, A.; et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J. Clin. Oncol. 2003, 21 (9), 1734-1739.
8. Canellos, G.P.; Niedzwiecki, D. Long-term follow-up of Hodgkin's disease trial. N. Engl. J. Med. 2002, 346 (18), 1417-1418.
9. Hasenclever, D.; Diehl, V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N. Engl. J. Med. 1998, 339 (21), 1506-1514.
10. Raemaekers, J.; Kluin-Nelemans, H.; Teodorovic, I.; et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur. J. Cancer 2002, 38 (Suppl. 4), S107-S113.